- Home
- MPB vs PHAR Comparison
MPB vs PHAR Comparison
Compare MPB & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPB
- PHAR
- Stock Information
- Founded
- MPB 1868
- PHAR 1988
- Country
- MPB United States
- PHAR Netherlands
- Employees
- MPB N/A
- PHAR N/A
- Industry
- MPB Major Banks
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- MPB Finance
- PHAR Health Care
- Exchange
- MPB Nasdaq
- PHAR Nasdaq
- Market Cap
- MPB 641.4M
- PHAR 718.1M
- IPO Year
- MPB N/A
- PHAR N/A
- Fundamental
- Price
- MPB $30.22
- PHAR $10.27
- Analyst Decision
- MPB Buy
- PHAR Strong Buy
- Analyst Count
- MPB 2
- PHAR 3
- Target Price
- MPB $36.00
- PHAR $30.00
- AVG Volume (30 Days)
- MPB 100.5K
- PHAR 4.3K
- Earning Date
- MPB 07-23-2025
- PHAR 07-31-2025
- Dividend Yield
- MPB 2.65%
- PHAR N/A
- EPS Growth
- MPB 23.94
- PHAR N/A
- EPS
- MPB 2.88
- PHAR N/A
- Revenue
- MPB $181,865,000.00
- PHAR $320,708,000.00
- Revenue This Year
- MPB $24.31
- PHAR $13.31
- Revenue Next Year
- MPB $13.74
- PHAR $7.68
- P/E Ratio
- MPB $10.50
- PHAR N/A
- Revenue Growth
- MPB 9.21
- PHAR 24.13
- 52 Week Low
- MPB $21.11
- PHAR $6.65
- 52 Week High
- MPB $33.87
- PHAR $12.61
- Technical
- Relative Strength Index (RSI)
- MPB 76.73
- PHAR 48.21
- Support Level
- MPB $28.02
- PHAR $10.46
- Resistance Level
- MPB $28.48
- PHAR $11.49
- Average True Range (ATR)
- MPB 0.62
- PHAR 0.37
- MACD
- MPB 0.35
- PHAR -0.12
- Stochastic Oscillator
- MPB 99.52
- PHAR 27.62
About MPB Mid Penn Bancorp
Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.